VISCHER advised Synendos in closing CHF 20 million Series A financing round

Synendos Therapeutics, a biopharmaceutical company developing a new class of small molecules designed to restore the natural function of the endocannabinoid system in the brain and have the potential to treat a variety of central nervous system (CNS) disorders , closed its Series A financing round of CHF 20 million. 

The financing was carried out under the joint management of Kurma Partners and Sunstone Life Science Ventures with the participation of BERNINA BioInvest, Schroder Adveq, High-Tech Gründerfonds, Lichtsteiner Foundation, Essential Investments, Zürcher Kantonalbank and private investors. Synendos will primarily use the funds raised to

The team 

VISCHER advised Synendos on all legal issues in connection with the transaction. The team included Christian Wyss (Partner, Corporate / M&A – pictured), Luzius Zumstein (Senior Associate, Corporate / M&A) and Dario Glauser (Trainee, Corporate / M&A).

VISCHER advised Synendos in closing CHF 20 million Series A financing round

FabioAdmin

Legalcommunity.ch

Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website www.lcpublishinggroup.com

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2022 © All rights Reserved. Design by Origami Creative Studio

SHARE

Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram